Key Metrics of Erasca Inc.
Revenue—FY 2023
Operating income−$142M▲ 42.8% YoY
Net profit−$125M▲ 48.5% YoY
Shareholders' equity$317M
Market cap$4.9BERAS · $14.04
Competitors10identified
About Erasca Inc.
Sectors
Company details
- Founded
- 2021
- Listed
- Nasdaq: ERAS (since 2021)
Operational Areas of Erasca Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameErasca Inc.
TickerERAS
ExchangeNasdaq
CountryUnited States
SEC CIK0001761918
Listed since2021
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ERAS · Nasdaq · SEC CIK 0001761918
Last price · 24 Oct 2026
$14.04
−3.11%
Market cap$4.9B
P/E—On FY 2023 diluted EPS
Volume2,296,102
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2021
ERAS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Erasca Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.